Volume : 12, Issue : 10, October – 2025
Title:
A STUDY ON EFFICACY OF CITICOLINE AND EDARAVONE IN ACUTE ISCHEMIC STROKE
Authors :
Dr. Gudapati Manoj Kumar, Dr. Karupalli Meena Sri, Dr. Shashank Pillarisetti , Dr. J John Kirubakaran
Abstract :
Background: Acute ischemic stroke (AIS) is a leading cause of morbidity and mortality worldwide. Citicoline and Edaravone are neuroprotective agents with distinct mechanisms of action.
Objective: To compare the efficacy of Citicoline and Edaravone in patients with AIS using the National Institute of Health Stroke Scale (NIHSS) and Modified Rankin Scale (mRS).
Methods: A prospective hospital-based study was conducted at KIMS Hospital, Rajahmundry, Andhra Pradesh, India, between September 2022 and March 2023. Seventy-four patients diagnosed with AIS were randomized into two groups: Citicoline (n=35) and Edaravone (n=39). Clinical data, vascular risk factors, NIHSS, and mRS scores were assessed at baseline, discharge, day 14, and day 30. Statistical analyses included Levene’s test, descriptive statistics, and post-hoc comparisons.
Results: Males predominated in both groups (63% Citicoline, 62% Edaravone). The majority were aged 61–70 years. Diabetes (36%) was the most common vascular risk factor. Both groups showed significant improvement in NIHSS and mRS scores from baseline to day 30. However, Edaravone demonstrated greater efficacy with significantly lower mean NIHSS (0.41 ± 0.88) and mRS (0.42 ± 1.06) scores at day 30 compared to Citicoline (NIHSS 2.37 ± 7.05, mRS 0.92 ± 0.73; p<0.05).
Conclusion: Both agents improved outcomes, but Edaravone was superior in reducing stroke severity and disability within 30 days. Larger multicenter trials with long-term follow-up are warranted.
Keywords: Acute ischemic stroke, Citicoline, Edaravone, NIHSS, Modified Rankin Scale, Neuroprotection
Cite This Article:
Please cite this article in press Shashank Pillarisetti et al., A Study On Efficacy Of Citicoline And Edaravone In Acute Ischemic Stroke, Indo Am. J. P. Sci, 2025; 12(10).
REFERENCES:
1. Hasan TF, Hasan H, Kelley RE. Overview of Acute Ischemic Stroke Evaluation and Management. Biomedicines. 2021 Oct 16;9(10):1486.
2. Musuka T.D., Wilton S.B., Traboulsi M., Hill M.D. Diagnosis and management of acute ischemic stroke: Speed is critical. Can. Med. Assoc. J. 2015;187:887–893
3. Kuriakose D, Xiao Z. Pathophysiology and Treatment of Stroke: Present Status and Future Perspectives. Int J Mol Sci. 2020 Oct 15;21(20):7609.
4. Su Z, Ye Y, Shen C, Qiu S, Sun Y, Hu S, Xiong X, Li Y, Li L, Wang H. Pathophysiology of Ischemic Stroke: Noncoding RNA Role in Oxidative Stress. Oxid Med Cell Longev. 2022 Sep 12;2022:5815843
5. Lee BJ, Egi Y, van Leyen K, Lo EH, Arai K. Edaravone, a free radical scavenger, protects components of the neurovascular unit against oxidative stress in vitro. Brain Res. 2010 Jan 11;1307:22-7.
6. Song Y, Bei Y, Xiao Y, Tong HD, Wu XQ, Chen MT. Edaravone, a free radical scavenger, protects neuronal cells’ mitochondria from ischemia by inactivating another new critical factor of the 5-lipoxygenase pathway affecting the arachidonic acid metabolism. Brain Res. 2018 Jul 1;1690:96-104.
7. Chen C, Li M, Lin L, Chen S, Chen Y, Hong L. Clinical effects and safety of edaravone in treatment of acute ischaemic stroke: A meta-analysis of randomized controlled trials. J Clin Pharm Ther. 2021 Aug;46(4):907-917.
8. Gareri P, Castagna A, Cotroneo AM, Putignano S, De Sarro G, Bruni AC. The role of citicoline in cognitive impairment: pharmacological characteristics, possible advantages, and doubts for an old drug with new perspectives. Clin Interv Aging. 2015 Sep 3;10:1421-9.
9. Li M, Huo X, Chang Q, Liu X, Zhang J, Mao Z. Efficacy analysis of neuroprotective drugs in patients with acute ischemic stroke based on network meta-analysis. Front Pharmacol. 2024 Nov 7;15:1475021.
10. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics—2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56-528.
11. Banerjee, T. K., & Das, S. K. Fifty years of stroke researches in India. Annals of Indian Academy of Neurology. 2016;19(1):1-8.
12. Mitta M, Goel D, Bansal KK, Puri P. Edaravone – citicoline comparative study in acute ischemic stroke (ECCS-AIS). J Assoc Physicians India. 2012 Nov;60:36-8.
13. Sadi AM, Khadeeja M, Periera LJ, John C, Lakshmi R, Soumya VC. A Comparative Study of Stroke Outcomes in Patients Receiving Edaravone and Citicoline. Indian J Pharmacy Practice. 2025;18(4):404-9.
14. Ogawa Y, Akiyama H, Horii T, Mihara K. Association between edaravone use and activities of daily living in older patients with atherothrombotic stroke: an observational study using Japanese real-world data. BMC Geriatr. 2025 Jan 15;25(1):31.
15. Dávalos A, Alvarez-Sabín J, Castillo J, Díez-Tejedor E, Ferro J, Martínez-Vila E, Serena J, Segura T, Cruz VT, Masjuan J, Cobo E, Secades JJ; International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet. 2012 Jul 28;380(9839):349-57
16. Wang Y, Li M, Jiang Y, Ji Q. Comparative efficacy of neuroprotective agents for improving neurological function and prognosis in acute ischemic stroke: a network meta-analysis. Front Neurosci. 2025 Jan 6;18:1530987.
17. Sadi, Aleena & Maitheen, Khadeeja & Periera, Laveena & John, Cijy & Ramachandran, Lakshmi & Chandrasekharan, Soumya. (2025). A Comparative Study of Stroke Outcomes in Patients Receiving Edaravone and Citicoline. Indian Journal of Pharmacy Practice. 18. 404-409.